215 related articles for article (PubMed ID: 8561866)
1. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
3. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
4. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
6. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
10. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia PL; Marsh DJ; Zheng Z; Zedenius J; Komminoth P; Frisk T; Wallin G; Parsons R; Longy M; Larsson C; Eng C
Cancer Res; 1997 Nov; 57(21):4710-3. PubMed ID: 9354427
[TBL] [Abstract][Full Text] [Related]
11. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity on chromosome 16p and 18q in anaplastic thyroid carcinoma.
Kadota M; Tamaki Y; Sekimoto M; Fujiwara Y; Aritake N; Hasegawa S; Kobayashi T; Ikeda T; Horii A; Monden M
Oncol Rep; 2003; 10(1):35-8. PubMed ID: 12469141
[TBL] [Abstract][Full Text] [Related]
13. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
14. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
Pollock PM; Pearson JV; Hayward NK
Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
16. p27/Kip1 mutation found in breast cancer.
Spirin KS; Simpson JF; Takeuchi S; Kawamata N; Miller CW; Koeffler HP
Cancer Res; 1996 May; 56(10):2400-4. PubMed ID: 8625318
[TBL] [Abstract][Full Text] [Related]
17. Rare loss of heterozygosity of the MTS1 and MTS2 tumor suppressor genes in differentiated human thyroid cancer.
Schulte KM; Staudt S; Niederacher D; Finken-Eigen M; Köhrer K; Goretzki PE; Röher HD
Horm Metab Res; 1998 Sep; 30(9):549-54. PubMed ID: 9808321
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
19. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA alterations in thyroid cancer.
Tong BC; Ha PK; Dhir K; Xing M; Westra WH; Sidransky D; Califano JA
J Surg Oncol; 2003 Mar; 82(3):170-3. PubMed ID: 12619060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]